Abdominal Pain News and Research

RSS

Abdominal pain is traditionally described by its chronicity (acute or chronic), its progression over time, its nature (sharp, dull, colicky), its distribution (by various methods, such as abdominal quadrant (left upper quadrant, left lower quadrant, right upper quadrant, right lower quadrant) or other methods that divide the abdomen into nine sections), and by characterization of the factors that make it worse, or alleviate it.

Soy products meet nutritional needs of people with lactose intolerance

Today, nutrition experts and physicians who participated in the NIH Consensus Development Conference on Lactose Intolerance and Health released an important report that concluded individuals who ingest inadequate amounts of calcium and vitamin D because of real or perceived lactose intolerance need dietary advice to ensure appropriate intake of missing nutrients.

25 Feb 2010

FDA Gastrointestinal Drugs Advisory Committee supports approval of XIFAXAN 550 mg for management of HE

Salix Pharmaceuticals, Ltd. today reported that the Gastrointestinal Drugs Advisory Committee of the FDA has recommended by a vote of 14 to 4 in favor of the approval of XIFAXAN® (rifaximin) Tablets, 550 mg for the maintenance of remission of hepatic encephalopathy (HE).

23 Feb 2010

Genentech's Avastin combination Phase III study in advanced stomach cancer does not meet primary endpoint

Genentech, Inc., a wholly owned member of the Roche Group, today announced that a Phase III study (AVAGAST) did not meet its primary endpoint of showing Avastin® (bevacizumab) plus Xeloda® (capecitabine) or 5-FU and cisplatin chemotherapy extended the lives of people with inoperable or advanced stomach (gastric) cancer, compared to chemotherapy alone.

23 Feb 2010

FDA issues approval for Gileads's Cayston for respiratory symptoms in cystic fibrosis

Gilead Sciences, Inc. today announced that the U.S. Food and Drug Administration (FDA) has granted marketing approval for Cayston® (aztreonam for inhalation solution) as a treatment to improve respiratory symptoms in cystic fibrosis patients with Pseudomonas aeruginosa. Cayston’s safety and efficacy have not been established in pediatric patients below the age of 7, patients with forced expiratory volume in one second of less than 25 percent or greater than 75 percent predicted, or patients colonized with Burkholderia cepacia.

23 Feb 2010

Humans can harbor bacteria in gallstones, infect others with active typhoid fever

A new study suggests that the bacteria that cause typhoid fever collect in tiny but persistent communities on gallstones, making the infection particularly hard to fight in so-called "carriers" - people who have the disease but show no symptoms.

23 Feb 2010

Phase 3b ODIN study of once-daily PREZISTA in HIV-1 adults presented at CROI 2010

In a new study of treatment-experienced HIV-1-infected adults with no PREZISTA® (darunavir) resistance-associated mutations (RAMs), 72 percent of patients in the PREZISTA/ritonavir (r) (800/100 mg) once-daily arm achieved undetectable viral loads (<50 copies/mL) compared with 71 percent of patients in the PREZISTA/r (600/100 mg) twice-daily arm. The study met its primary objective of non-inferiority. These data from the Phase 3b ODIN study were presented today at CROI 2010, the 17th Conference on Retroviruses and Opportunistic Infections, in San Francisco.

18 Feb 2010

Study demonstrates usefulness of salivary diagnostics in finding pancreatic cancer

The good news is that there may soon be a new weapon in the battle against the so-called "worst" cancer - cancer of the pancreas. A multidisciplinary group of investigators from the UCLA School of Dentistry, the David Geffen School of Medicine at UCLA, the UCLA School of Public Health and UCLA's Jonsson Comprehensive Cancer Center has demonstrated the usefulness of salivary diagnostics in the effort to find and fight the disease.

17 Feb 2010

Mayo Clinic Health Letter features comprehensive coverage of the liver

The liver, the largest internal organ, is the body's ultimate multitasker. While the liver is not glamorous or sentimental -- there are no love songs about a broken liver -- it simultaneously plays a key role in the body's metabolic, digestive and regulatory systems.

12 Feb 2010

Genzyme announces 2-year data from eliglustat tartrate Phase 2 trial for Gaucher disease

Genzyme Corporation announced today two-year follow-up data from patients enrolled in the phase 2 clinical trial for its investigational oral therapy for Gaucher disease type 1 known as eliglustat tartrate (formerly Genz-112638). Continued improvements were observed across all endpoints, including bone disease, at the two-year timepoint, compared with baseline. The two-year results were presented for the first time today at the Lysosomal Disease Network WORLD Symposium in Miami, Fla.

12 Feb 2010

Positive results from Shire's velaglucerase alfa Phase III study for Type 1 Gaucher disease

Shire plc, the global specialty biopharmaceutical company, today presented positive results from its first Phase III study (TKT 032) evaluating safety and efficacy of velaglucerase alfa, its investigational enzyme replacement therapy for the treatment of Type 1 Gaucher disease. The data were presented in an oral presentation at the Lysosomal Disease Network (LDN) World Symposium in Miami, Florida.

12 Feb 2010

FDA grants approval for Abbott's antiretroviral medication Norvir

Abbott announced today that the U.S. Food and Drug Administration (FDA) has granted approval of a new tablet formulation of the company's antiretroviral medication Norvir ® (ritonavir). The new Norvir tablets can be stored at room temperature and do not require refrigeration, making it more convenient for patients.

11 Feb 2010

Concomitant use of dexlansoprazole and other PPIs with Plavix: TGRD U.S. initiates trial

Takeda Global Research & Development Center, Inc., U.S., (TGRD U.S.) announced today that it has initiated a trial to study how dexlansoprazole and several other proton pump inhibitors (PPIs) affect the pharmacokinetics and pharmacodynamics of Plavix (clopidogrel bisulfate) in healthy subjects. Takeda has been evaluating all published data and communications from the U.S. Food and Drug Administration (FDA) regarding the potential risks associated with concomitant use of clopidogrel and PPIs.

10 Feb 2010

Acupuncture: An effective pain management therapy for pediatric patients

Doctors at Rush University Medical Center are offering pediatric patients diagnosed with chronic illnesses acupuncture therapy to help ease the pain and negative side effects like nausea, fatigue, and vomiting caused by chronic health conditions and intensive treatments.

10 Feb 2010

CREON effective in improving CFA and CNA in pediatric patients with EPI due to CF

Solvay Pharmaceuticals, Inc. announced that Phase IIIb data published in the January issue of Clinical Therapeutics confirm that CREON® (pancrelipase) Delayed-Release Capsules significantly improves a key measure of fat absorption in children aged 7-11 years who have exocrine pancreatic insufficiency (EPI) due to cystic fibrosis (CF), EPI is a condition resulting from a deficiency in the production and/or secretion of pancreatic enzymes that are necessary to digest nutrients in food.

5 Feb 2010

FDA investigates Salmonella Montevideo outbreak in Italian sausage products

The Food and Drug Administration, along with the Centers for Disease Control and Prevention and the U.S. Department of Agriculture's Food Safety and Inspection Service, continues to work closely with the Rhode Island Department of Health and other states in the investigation of an outbreak of Salmonella Montevideo infections associated with certain Italian-style sausage products including salami/salame.

5 Feb 2010

Romark Laboratories commences enrollment in Alinia clinical trial for acute uncomplicated influenza

Romark Laboratories announced that it has initiated enrollment of patients in a clinical trial of Alinia® (nitazoxanide) for treating acute uncomplicated influenza including illness caused by the currently circulating H1N1 strain.

1 Feb 2010

How to recognize heart attack symptoms in younger women

The risk for heart-related death is increasing in young adults ages 35 to 54, and the numbers are even more alarming for younger women. It is the number-one cause of death for both men and women in the United States, yet every year since 1984 more women have died of cardiovascular health problems than men, according to the American Heart Association.

29 Jan 2010

Labeling update for Tibotec Therapeutics' PREZISTA tablets approved

Tibotec Therapeutics announced today that the U.S. Food and Drug Administration (FDA) has approved a labeling update for PREZISTA® (darunavir) tablets to include 96-week data from the ARTEMIS and TITAN studies.

29 Jan 2010

DNA variations in genes increase risk of developing PI-IBS

Studies of the victims of the Walkerton, Ont. tainted drinking water tragedy have led researchers to discover DNA variations in genes that increase the risk of developing post-infectious irritable bowel syndrome (PI-IBS). The sheer scale of infection and the recording of the health of Walkerton's citizens gave a team of researchers a unique opportunity to study the origin of this disorder.

28 Jan 2010

Health Canada approves first post-surgical treatment for patients with gastrointestinal stromal tumours

Patients with gastrointestinal stromal tumours (GIST) can now take action at an earlier stage of this rare form of cancer to reduce the risk of their disease returning following surgery. Novartis Pharmaceuticals Canada announced today that Gleevec* (imatinib mesylate) has received conditional approval by Health Canada for the adjuvant (post-surgical) treatment of adult patients who are at intermediate to high risk of disease recurrence following the surgical removal of GIST.

27 Jan 2010

Abdominal Pain News and Research

Further Reading

Soy products meet nutritional needs of people with lactose intolerance

FDA Gastrointestinal Drugs Advisory Committee supports approval of XIFAXAN 550 mg for management of HE

Genentech's Avastin combination Phase III study in advanced stomach cancer does not meet primary endpoint

FDA issues approval for Gileads's Cayston for respiratory symptoms in cystic fibrosis

Humans can harbor bacteria in gallstones, infect others with active typhoid fever

Phase 3b ODIN study of once-daily PREZISTA in HIV-1 adults presented at CROI 2010

Study demonstrates usefulness of salivary diagnostics in finding pancreatic cancer

Mayo Clinic Health Letter features comprehensive coverage of the liver

Genzyme announces 2-year data from eliglustat tartrate Phase 2 trial for Gaucher disease

Positive results from Shire's velaglucerase alfa Phase III study for Type 1 Gaucher disease

FDA grants approval for Abbott's antiretroviral medication Norvir

Concomitant use of dexlansoprazole and other PPIs with Plavix: TGRD U.S. initiates trial

Acupuncture: An effective pain management therapy for pediatric patients

CREON effective in improving CFA and CNA in pediatric patients with EPI due to CF

FDA investigates Salmonella Montevideo outbreak in Italian sausage products

Romark Laboratories commences enrollment in Alinia clinical trial for acute uncomplicated influenza

How to recognize heart attack symptoms in younger women

Labeling update for Tibotec Therapeutics' PREZISTA tablets approved

DNA variations in genes increase risk of developing PI-IBS

Health Canada approves first post-surgical treatment for patients with gastrointestinal stromal tumours

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News